How much does Bituvi/Bikonprenol tablets cost after medical insurance reimburses them? Interpretation of the latest prices and policies in 2025
Biktarvy is an antiviral drug used to treat HIV infection and belongs to the integrase inhibitor class. It interferes with the HIV genome integration process, thereby effectively preventing the virus from replicating in host cells. This mechanism makes Bituvi a very important anti-HIV treatment option, especially in drug-resistant cases, with remarkable efficacy.
In terms of indications, Bituvi is mainly used to treat HIV-1 infection in adults and children, especially those who have not received antiviral treatment and those who are resistant to other treatment options. Bituvir is often used in combination with other antiviral drugs to increase the effectiveness of treatment, reduce viral load, and promote the recovery of immune function. In addition, due to its good tolerability and relatively few adverse reactions, Bitover has gradually become one of the first-choice drugs recommended clinically.

Currently, Bituvi has been launched in the Chinese market and has been included in the scope of medical insurance reimbursement. This reduces the financial burden for HIV patients who require long-term antiviral treatment. According to the latest market price, a 30-capsule package of Bituvit costs approximately more than 1,000 yuan. However, the specific amount of medical insurance reimbursement will vary by region and hospital. Usually, the costs that patients need to bear after medical insurance reimbursement will be significantly reduced, making it more affordable.
It is worth noting that despite its relatively high price, its efficacy and potential to improve quality of life make many patients willing to choose this drug. Especially in China, faced with the public health challenge of HIV infection, the popularization and application of Bituvi will help control the development of the epidemic and improve the survival rate and quality of life of patients.
Reference materials:https://www.biktarvy.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)